T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic stem cell ...

Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...

Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...

Researchers at the University of Southampton have developed a promising new way to bolster the body’s immune system response to cancer. In a study published in Nature Communications, researchers used ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...